SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as investors aggressively accumulate ahead of anticipated institutional partnerships and the potential passing of the Clarity Act. While some community members remain skeptical, many are focused on the project's utility in the agentic AI economy and its ongoing infrastructure integration with major financial networks.

Unicycive Therapeutics, Inc. is a biotechnology company, which engages in developing novel treatments for kidney diseases. The firm investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

Unicycive Therapeutics Inc

Unicycive Therapeutics is trending as investors monitor ongoing discussions with the FDA regarding the OLC manufacturing deficiency, which the community views as a critical path toward the June 29 PDUFA date. Discussions are heavily focused on the company's ability to maintain a clear regulatory timeline while balancing cash reserves and shareholder concerns about equity dilution.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Roku is attracting intense attention as institutional investors weigh the potential for a growth turnaround following positive earnings and analyst upgrades, while speculation regarding a possible acquisition continues to fuel community debate. Traders are closely monitoring the stock's ability to maintain upward momentum as it approaches key resistance levels amid broader index volatility.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

Polkadot is facing intense scrutiny as investors debate its long-term viability amid ongoing price volatility, with community sentiment deeply divided between those betting on its technical potential and others dismissing it as a failing project. Discussions are heavily focused on the impact of upcoming tokenomics shifts, the progress of Polkadot 2.0, and whether the network can generate sufficient real-world adoption to trigger a meaningful recovery.

Global X Funds - Global X DAX Germany ETF

Global X DAX Germany ETF

The DAX is trending as traders closely monitor Elliott Wave technical patterns and potential high-frequency buying opportunities amid ongoing geopolitical tensions and trade negotiations. The community remains focused on whether the index will maintain its recent bullish momentum or face a corrective pullback following a period of significant gains.

Canton Coin (CC), the network’s native utility token, was designed to reward real network usage over speculation. It aligns the success of the network with the participants who make it work, fairly rewarding app builders and app users, as well as those operating decentralized infrastructure. The result is a fundamentally different model where rewards flow to those creating value through real activity, not only miners or early investors.

Canton

The Canton Network is garnering significant attention as investors react to its institutional adoption and the onboarding of major financial players as validators, while community members debate the long-term impact of supply unlocks and burn mechanisms on the token's price performance.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

Compass Pathways is trending following the FDA's decision to grant a rolling review and a Commissioner's National Priority Voucher for its COMP360 treatment, fueling intense community discussion about the company's potential as a first-mover in the psychedelic psychiatry space. Investors are closely monitoring upcoming durability data and corporate presentations as catalysts, with many weighing the firm's commercialization strategy against the backdrop of broader biotech volatility.

Domino's Pizza, Inc. engages in the management of a network of company-owned and franchise-owned pizza stores. It operates through the following segments: U.S. Stores, International Franchise, and Supply Chain. The U.S. Stores segment consists primarily of franchise operations. The International Franchise segment comprises a network of franchised stores. The Supply Chain segment manages regional dough manufacturing and food supply chain centers. The company was founded by James Monaghan and Thomas Stephen Monaghan in 1960 and is headquartered in Ann Arbor, MI.

Dominos Pizza Inc

Dominos is drawing significant investor attention as market participants weigh its recent earnings report, which highlighted positive domestic sales growth alongside broader industry concerns over consumer discretionary spending. The community is actively debating the stock's long-term value and competitive positioning, with many retail traders focusing on its potential for a turnaround after recent price fluctuations.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor is trending as market participants increasingly view it as a leading infrastructure project for decentralized AI, with significant community excitement surrounding institutional interest, ETF filings, and its role as a "Bitcoin of AI." While some investors voice concerns over subnet volatility and governance centralization, many are using recent price dips as accumulation opportunities, focusing on the long-term utility of its decentralized intelligence network.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics (DFTX) is trending due to anticipation of multiple Phase 3 topline data readouts this year, with investors focused on the company's well-funded clinical pipeline and its position following recent executive order support for psychedelic research. Community sentiment remains polarized, characterized by bullish optimism regarding the company's potential to re-rate upon positive results, contrasted by significant concern from bears regarding historical management issues, cash burn, and the potential for future equity dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

JPMorgan⬆️ $IDYA $74 from $72/reit&#39;d OW ~it believes $IDYA&#39;s early-stage updates for IDE849 / IDE397 can drive investor interest in the pipeline beyond darovasertib. 
$PFE $GILD $DSNKY $AZN RHHBY 
JPMorgan said in its note to investors: IDEAYA Biosciences is an emerging company in the precision-oncology space. 
Importantly, Ideaya&#39;s lead asset, darovasertib (IDE196), has established proof-of-concept (POC) within uveal melanoma. 
Net-net, we continue to see darovasertib, especially in the metastatic uveal melanoma (MUM) setting, as de-risked. 
 
On the broader pipeline beyond darovasertib in 
MUM, it is &quot;choose your favorite adventure scenario&quot;, which provides interesting long-term optionality (we think darovasertib in neoadjuvant is underappreciated). 
 
Looking forward, we anticipate focus on updates for darovasertib (metastatic / neoadjuvant settings), IDE397, and IDE849 programs. Our Overweight rating on $IDYA shares is based on the potential of darovasertib and broad synthetic lethality pipeline.

Mizuho⬇️ $IDYA PT to $43 from $55, keeps at Outperform &amp; says, &quot;Given a fresh review of $IDYA&#39;s pipeline (a deep one, consisting of nine assets that are all expected to be in the clinic by YE25), we now reflect on multiple updates. 
 
Most notably, while timing of a first pivotal study efficacy readout for lead asset darovasertib/daro (for metasatic uveal melanoma/MUM) is now expected by YE25 (reflecting a tightening of timelines), for $IDYA&#39;s second most important pipeline asset, IDE397 (a novel MAT2A inhibitor), we now push out (slightly) our launch timing assumption, given news earlier this year of a dissolution of a key partnership. 
 
Bigger picture, we&#39;ve made several model revisions (see within; mainly, non-pipeline-related), and net-net, our PT moves 22% lower to $43 from $55. That said, with significant pipeline optionality (and hence, model upside) - given six of $IDYA&#39;s nine assets yet to be reflected in our model - and in light of current risk/reward, we stay OP-rated on $IDYA.&quot;

StockTwits Web

Ideaya Biosciences Inc

Quantumup

Barclays🏁 $IDYA Overweight/$40. 
Citizens🏁 $IDYA Market Outperform/$41. 
$ZLAB $AMGN $DSNKY $PFE GILD AZN RHHBY  
 
Barclays and Citizens JMP said in their initiation reports:

Pfizer Inc

Gilead Sciences, Inc.

Daiichi Sankyo Company

AstraZeneca PLC

's early-stage updates for IDE849 / IDE397 can drive investor interest in the pipeline beyond darovasertib. 


 RHHBY 
JPMorgan said in its note to investors: IDEAYA Biosciences is an emerging company in the precision-oncology space. 
Importantly, Ideaya's lead asset, darovasertib (IDE196), has established proof-of-concept (POC) within uveal melanoma. 
Net-net, we continue to see darovasertib, especially in the metastatic uveal melanoma (MUM) setting, as de-risked. 
 
On the broader pipeline beyond darovasertib in 
MUM, it is "choose your favorite adventure scenario", which provides interesting long-term optionality (we think darovasertib in neoadjuvant is underappreciated). 
 
Looking forward, we anticipate focus on updates for darovasertib (metastatic / neoadjuvant settings), IDE397, and IDE849 programs. Our Overweight rating on 

 shares is based on the potential of darovasertib and broad synthetic lethality pipeline.